

**Author(s):** CMM/MN/AT

**Date:** 2015-05-28

**Question:** Should muscle tension in children 7 years and above and adults with a history of fainting vs control be used for reducing fainting during vaccine injections?

**Settings:** hospital, university

**Bibliography:** Brignole 2002, van Dijk 2006, Vogeles 2003

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Muscle tension in children 7 years and above and adults with a history of fainting	Control	Relative (95% CI)	Absolute		
Number with fainting over 12 month followup period (assessed with: self-report on a log book)												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	very serious <sup>2</sup>	serious <sup>3</sup>	none	31/98 (31.6%)	56/110 (50.9%)	RR 0.62 (0.44 to 0.88)	193 fewer per 1000 (from 61 fewer to 285 fewer)	⊕○○○ VERY LOW	CRITICAL
								0%		-		
Number with fainting during procedure <sup>4</sup> (assessed with: observation by researcher)												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	very serious <sup>6</sup>	serious <sup>3</sup>	none	1/19 (5.3%)	9/19 (47.4%)	RR 0.11 (0.02 to 0.79) <sup>4</sup>	422 fewer per 1000 (from 99 fewer to 464 fewer)	⊕○○○ VERY LOW	CRITICAL
								0%		-		
Number with fainting during procedure recovery (assessed with: observation by researcher)												
1	randomised trials	serious <sup>5</sup>	no serious inconsistency	very serious <sup>6</sup>	serious <sup>7</sup>	none	3/19 (15.8%)	2/19 (10.5%)	RR 1.5 (0.28 to 7.99)	53 more per 1000 (from 76 fewer to 736 more)	⊕○○○ VERY LOW	CRITICAL
								0%		-		
Number of fainting episodes per patient per year (measured with: self-report log book; Better indicated by lower values)												
1	randomised	serious <sup>1</sup>	no serious	very serious <sup>2</sup>	serious <sup>3</sup>	none	98	110	-	SMD 3.32 lower (3.74 to 2.9)	⊕○○○ VERY	CRITICAL

	trials		inconsistency							lower)	LOW	
<b>Time to recurrence of fainting (measured with: self-report log; Better indicated by higher values)</b>												
1	randomised trials	serious <sup>1</sup>	no serious inconsistency	very serious <sup>2</sup>	serious <sup>7</sup>	none	31	56	-	SMD 0.33 lower (0.77 lower to 0.11 higher)	⊕000 VERY LOW	CRITICAL
<b>Fear Pre-procedure (post-intervention)<sup>8</sup> (measured with: validated tool (Symptom-Emotion-Checklist 0-100) ; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>9</sup>	no serious inconsistency	very serious <sup>10</sup>	serious <sup>7</sup>	none	11	11	-	SMD 0.95 higher (0.06 to 1.85 higher) <sup>8,11</sup>	⊕000 VERY LOW	IMPORTANT
<b>Fear Acute<sup>8</sup> (measured with: validated tool (Symptom-Emotion-Checklist 0-100) ; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>9</sup>	no serious inconsistency	very serious <sup>10</sup>	serious <sup>7</sup>	none	11	11	-	SMD 0.21 higher (0.63 lower to 1.05 higher) <sup>8,11</sup>	⊕000 VERY LOW	IMPORTANT
<b>Fear Recovery<sup>8</sup> (measured with: validated tool (Symptom-Emotion-Checklist 0-100) ; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>9</sup>	no serious inconsistency	very serious <sup>10</sup>	serious <sup>7</sup>	none	11	11	-	SMD 0.65 higher (0.21 lower to 1.52 higher) <sup>8,11</sup>	⊕000 VERY LOW	IMPORTANT
<b>Lightheadedness, Nausea, Sweaty hands, Racing heart (i.e., prodromal sign of fainting) (measured with: validated tool (each measured with Symptom-Emotion-Checklist 0-100) ; Better indicated by lower values)</b>												
1	randomised trials	serious <sup>9</sup>	no serious inconsistency	very serious <sup>10</sup>	serious <sup>7</sup>	none	11	11 <sup>11</sup>	-	not pooled	⊕000 VERY LOW	IMPORTANT
<b>Pain, Distress, Procedure Outcomes, Vaccine Compliance, Preference, Satisfaction (assessed with: no data were identified for these important outcomes)</b>												
0	No evidence available					none	-	-	-	-		IMPORTANT
								0%		-		

<sup>1</sup> Clinicians collecting followup data were not blinded; participants were blinded; participants reported outcomes

<sup>2</sup> In included study (van Dijk 2006), patients had a confirmed history of vaso-vagal syncope but did not undergo vaccination or any other procedure. Naturally occurring syncopal episodes were recorded over a 12 month followup period.

<sup>3</sup> Sample size was below the recommended optimum information size (OIS) of 400 for an effect size of 0.2

<sup>4</sup> In excluded study (Vogele 2003), 2/11 individuals with a history of fainting in the control group (attention control) fainted while watching a surgical film vs. 0/11 individuals with a history of fainting in the intervention group (muscle tension).

<sup>5</sup> Clinicians collecting data were not blinded; participants were blinded; clinicians reported study outcomes.

<sup>6</sup> In included study (Brignole 2002), patients had a confirmed history of vaso-vagal syncope and underwent a procedure (tilt table testing).

<sup>7</sup> Confidence intervals cross the line of nonsignificance and the sample size was below the recommended optimum information size (OIS) of 400 for an effect size of 0.2

<sup>8</sup> Additional data provided by author (Vogele 2003)

<sup>9</sup> No blinding

<sup>10</sup> In included study (Vogele 2003), individuals with self-reported history of feeling faint at the sight of blood or injury received instruction in the intervention (muscle tension) or control (attention control) then watched a surgical film.

<sup>11</sup> In included study (Vogele 2003), sample size assumed to be 11/group.